AKTS

Aktis Oncology, Inc. (AKTS) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Aktis Oncology, Inc. is a clinical-stage oncology company developing targeted radiopharmaceuticals using a proprietary miniprotein radioconjugate platform. The company focuses on expanding the use of alpha-emitting radioisotopes to treat solid tumors. Key product candidates include [225Ac]Ac-AKY-1189 (targeting Nectin-4) and [225Ac]Ac-AKY-2519 (targeting B7-H3). The company completed its Initial Public Offering (IPO) in January 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Collaboration revenue increased to $3.4 million for the quarter (from $1.6 million in Q2 2025) and $6.6 million for the six months (from $3.0 million in the prior year period), driven by the Eli Lilly collaboration agreement.
• Expense Increase: Total operating expenses rose to $32.3 million for the quarter and $58.2 million for the six months. This increase is primarily due to:
  • Advancement of clinical trials for [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519.
  • Increased headcount and associated stock-based compensation.
  • Higher general and administrative costs related to public company operations (legal, audit, insurance).
• Liquidity Expansion: Following the January 2026 IPO, which raised net proceeds of approximately $334.4 million, total cash, cash equivalents, and marketable securities grew from $227.4 million at year-end 2025 to $517.3 million as of June 30, 2026.
• Capital Structure: All redeemable convertible preferred stock was converted to common stock upon the IPO closing. No preferred stock remains outstanding.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring substantial losses as it advances clinical trials and expands manufacturing capabilities. The company believes its current liquidity of $517.3 million is sufficient to fund operations into 2029.
• Collaboration Milestones: One development milestone of $1.0 million under the Eli Lilly agreement has been achieved. The remaining transaction price of $48.2 million is expected to be recognized through 2030.
• Risks:
  • Capital Needs: The company has no committed sources of capital beyond current holdings and may require additional funding if clinical timelines extend or costs exceed expectations.
  • Development Risks: Success depends on the outcome of clinical trials, regulatory approvals, and the ability to secure a reliable supply of Actinium-225 (225Ac).
  • Profitability: The company has not generated revenue from product sales and does not expect to do so in the near future. Profitability is uncertain and may never be achieved.
• Unusual Items: The company recorded a full valuation allowance against deferred tax assets. Interest income increased significantly due to higher cash balances and prevailing interest rates.

Key Facts for Investor Verification

• Cash Runway: Verify the $517.3 million liquidity position and the management estimate of funding operations into 2029.
• Revenue Recognition: Confirm the $48.2 million remaining transaction price from the Eli Lilly collaboration and the timeline for recognition through 2030.
• Clinical Progress: Monitor the status of the Phase 1b trial for [225Ac]Ac-AKY-1189 and the IND-enabling studies for [225Ac]Ac-AKY-2519.
• Supply Chain: Assess the company's strategy for securing a stable supply of 225Ac, a critical and potentially scarce radioisotope.
• Burn Rate: Track the quarterly net loss and operating cash burn to ensure alignment with the projected runway.